Original Articles
Remdesivir for patients with COVID-19
Peter Wu and Andrew Morris
CMAJ January 06, 2021 cmaj.202505; DOI: https://doi.org/10.1503/cmaj.202505
Peter Wu
Department of Medicine (Wu, Morris) Division of Clinical Pharmacology & Toxicology (Wu) and Division of Infectious Diseases (Morris), University of Toronto; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Infectious Diseases (Morris), Sinai Health and University Health Network, Toronto, Ont.
Andrew Morris
Department of Medicine (Wu, Morris) Division of Clinical Pharmacology & Toxicology (Wu) and Division of Infectious Diseases (Morris), University of Toronto; Division of General Internal Medicine and Geriatrics (Wu), University Health Network; Division of Infectious Diseases (Morris), Sinai Health and University Health Network, Toronto, Ont.
In this issue
Article tools
Respond to this article
Remdesivir for patients with COVID-19
Peter Wu, Andrew Morris
CMAJ Jan 2021, cmaj.202505; DOI: 10.1503/cmaj.202505
Related Articles
- No related articles found.
Cited By...
- No citing articles found.